RxSight (RXST) EBITDA Margin (2020 - 2026)

RxSight (RXST) has reported EBITDA Margin for 7 consecutive years, with 40.9% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin rose 73.0% year-over-year to 40.9%; the trailing twelve-month figure through Jun 2026 stood at 43.21% (down 2880.0% YoY), and the FY2025 full-year result was 35.84%, down 947.0% from the prior year.
• EBITDA Margin climbed to 40.9% in Q2 2026 per RXST's latest filing, from 57.71% in the prior quarter.
• Across five years, EBITDA Margin topped out at 185.64% in Q1 2022 and bottomed at 93.18% in Q4 2022.
• Historically, EBITDA Margin has averaged 2.85% across 5 years, with a median of 30.39% in 2024.
• The widest YoY moves for EBITDA Margin: up 50524 bps in 2022, down 117226 bps in 2022.
• Over 5 years, EBITDA Margin stood at 93.18% in 2022, then soared by 59 bps to 38.02% in 2023, then surged by 43 bps to 21.56% in 2024, then slumped by 61 bps to 34.65% in 2025, then slipped by 18 bps to 40.9% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 40.9%, 57.71%, and 34.65% for Q2 2026, Q1 2026, and Q4 2025 respectively.